<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03769753</url>
  </required_header>
  <id_info>
    <org_study_id>18-489</org_study_id>
    <nct_id>NCT03769753</nct_id>
  </id_info>
  <brief_title>Trial of IRE in Cholangiocarcinoma</brief_title>
  <official_title>Trial Of IRE in Cholangiocarcinoma (TOnIC): Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test any good and bad side effects of surgery using IRE to
      treat cancer of the bile duct.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a prospective, single-center phase I study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients experiencing a clinically relevant complications</measure>
    <time_frame>within 30 days post-IRE</time_frame>
    <description>defined as CTCAE (version 5.0) grade 3 or higher complications</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>intraoperative use of IRE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with intraoperatively determined advanced unresectable PHC will be treated with IRE during the same surgical exploration session (N=20). Electrodes will be placed using ultrasound guidance. All electrodes will be placed by hepatopancreatobiliary surgeons with experience using IRE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IRE Device</intervention_name>
    <description>For use in ablating soft tissue</description>
    <arm_group_label>intraoperative use of IRE</arm_group_label>
    <other_name>The NanoKnife IRE device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Capable of providing written and oral informed consent in English

          -  Locally advanced disease based on preoperative work-up demonstrating that the tumor is
             unresectable due to portal vein, hepatic artery, and/or bile duct involvement,
             insufficient hypertrophy response of the future liver remnant after portal vein
             embolization, or patients not able to tolerate major liver surgery

          -  Found to be unresectable intraoperatively based on vascular, biliary, or lymph node
             (N2) involvement upon exploratory laparotomy

          -  Patients will be assessed for chemotherapy prior to treatment with IRE, but given the
             common problem of recurrent cholangitis, some patients will not be candidates for
             chemotherapy until after IRE is performed.

        Exclusion Criteria:

          -  Locally advanced PHC eligible and accepted for liver transplantation evaluation

          -  PHC with &gt; 5 cm extension along the common hepatic duct or common bile duct on
             preoperative imaging or intraoperative ultrasound

          -  Metastases to peritoneum, liver or other organs confirmed by percutaneous biopsy,
             staging laparoscopy or intraoperative frozen section

          -  Lymph node metastases beyond N2 stations, confirmed by intraoperative frozen sections
             or radiographic diagnosis

          -  History of cardiac disease:

               -  Congestive heart failure (NYHA class &gt;2)

               -  Active Coronary Artery Disease (defined as myocardial infarction within 6 months
                  prior to screening)

               -  Cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers
                  are permitted)

          -  Any implanted stimulation device (defined as implantable cardiac device and a
             pacemaker)

          -  Uncontrolled hypertension (blood pressure must be â‰¤160/95 mmHg at the time of
             screening on a stable antihypertensive regimen)

          -  Uncontrolled infections (&gt; grade 2 NCI-CTC, version 3.0)

          -  Epilepsy

          -  Both narrowing (sclerosis) of the main portal vein and a reduced diameter of either
             the common hepatic artery, celiac trunk or superior mesenteric artery of &gt;50%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T. Peter Kingham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>T. Peter Kingham, MD</last_name>
    <phone>212-639-5260</phone>
    <email>kinghamt@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William Jarnagin, MD</last_name>
    <phone>212-639-7601</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Consent and Follow up)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Peter Kingham, MD</last_name>
      <phone>212-639-5260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Consent and Follow up)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Peter Kingham, MD</last_name>
      <phone>212-639-5260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Consent and Follow up)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Peter Kingham, MD</last_name>
      <phone>212-639-5260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Commack (Consent and Follow up)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Peter Kingham, MD</last_name>
      <phone>212-639-5260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Consent and Follow Up)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Peter Kingham, MD</last_name>
      <phone>212-639-5260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Peter Kingham, MD</last_name>
      <phone>212-639-5260</phone>
    </contact>
    <contact_backup>
      <last_name>William Jarnagin, MD</last_name>
      <phone>212-639-7601</phone>
    </contact_backup>
    <investigator>
      <last_name>T. Peter Kingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Consent and Follow-up)</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Peter Kingham, MD</last_name>
      <phone>212-639-5260</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intraoperative use of IRE</keyword>
  <keyword>18-489</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

